Heartflow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024

October 14, 2024

Long-term outcomes data from ADVANCE-DK Registry with Heartflow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six presentations

New data build upon the growing body of clinical evidence supporting non-invasive FFRCT technology and plaque analysis in the diagnosis and management of coronary artery disease

MOUNTAIN VIEW, Calif. —Oct. 14, 2024 —Heartflow, the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will present seven-year data from the ADVANCE-DK study, a subset from the larger ADVANCE Registry, which evaluated utility and clinical outcomes of Heartflow's AI-enabled FFR_{CT} and Plaque Analysis in clinically stable, symptomatic patients with coronary artery disease (CAD). Data from the ADVANCE-DK study and other clinical studies will be presented at the 36th annual Transcatheter Cardiovascular Therapeutics® (TCT) conference, which will take place October 27-30, 2024 in Washington, D.C.

"The ADVANCE registry helps us better understand whether more complete revascularization, as defined by FFR_{CT}, is associated with improved long-term cardiovascular outcomes," said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer of Heartflow. "Three-year data from this registry confirmed that patients with both abnormal FFR_{CT} and high plaque burden had two-and-a-half to three times greater risk of adverse cardiac events compared to patients with only abnormal FFR_{CT} or high plaque volume. We are excited to present seven-year data and build on our body of evidence demonstrating FFR_{CT} and AI-enabled plaque assessment as non-invasive approaches which can help physicians better quantify CAD risk in their patients."

At TCT, Heartflow will also present:

- Late-breaking data evaluating the capacity of FFR_{CT} and coronary computed tomography angiography (CCTA) to rule out significant lesions in high-risk non-ST elevation acute coronary syndromes (NSTE-ACS).
- Data from FUTURE-AS, an international, prospective, multicenter registry of patients with severe aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR) being assessed for CAD with CCTA and FFR_{CT}.
- New data from FASTTRACK-CABG, a single-arm, multicenter, prospective study assessing safety and feasibility of bypass surgery in patients with complex CAD solely based on CCTA combined with FFR_{CT}.
- Data highlighting the value for pre-procedural planning of combining FFR_{CT}, virtual percutaneous coronary intervention (PCI), and myocardial mass.
- Analysis of initial FFR_{CT}-based virtual PCI for pre-procedural planning in the U.S.

Details of each presentation are as follows:

Title: Completeness of Revascularization by FFR_{CT} and Long-term Prognosis in Stable Angina: A Seven-Year Follow-up of the ADVANCE-DK Registry
Presenter: Kristian Taekker Madsen, M.D., Ph.D.
Date: Sunday, October 27, 2024
Time: 7:30-8:45 AM EDT
Session: TCT WorldLink Forum: Best Global Research in Coronary Imaging
Location: Presentation Theater 3, Innovation & Exhibit Hall (Halls A-C)

Title: TCT 288: Comparative Analysis of FFR Derived From CCTA, Murray Law-Based Quantitative Flow Ratio and Quantitative Flow Ratio at Sequential Side Branches in Patients With Complex CAD: Insights From the FASTTRACK CABG Study
Presenter: Kotaro Miyashita, M.D.
Date: Sunday, October 27, 2024
Time: 9:00-9:50 AM EDT
Session: Moderated Abstracts Station 2
Location: Innovation & Exhibit Hall (Halls A-C)

Title: TCT 172: Usefulness of FFR_{CT} to Exclude Hemodynamically Significant Lesions in High-Risk NSTE-ACS
Presenter: Georgios Tzimas, M.D.
Date: Monday, October 28, 2024
Time: 4:00-5:30 PM EDT

Session: Moderated Abstracts Station 2
Location: Innovation & Exhibit Hall (Halls A-C)

Title: TCT 830: Feasibility and Utility of Anatomical and Physiological Evaluation of Coronary Disease With Cardiac CT in Severe Aortic Stenosis (FUTURE-AS Registry)
Presenters: Abdul Rahman Ihdayhid, M.D., Ph.D.
Moderators: Philippe PM Garot, M.D., Marie-France Poulin, M.D.
Date: Tuesday, October 29, 2024
Time: 8:00-9:00 AM EDT
Session: TAVR and CAD – 1
Location: Moderated Abstracts Station 5, Innovation & Exhibit Hall (Halls A-C)

Title: TCT 221: Coronary Computed Tomography Angiography-Guided Bifurcation Percutaneous Coronary Intervention: Role of FFR_{CT} Virtual PCI and Myocardial Mass for Pre-Procedural Planning
Presenters: Pedro Carvalho, M.D.
Moderators: Hector M. Garcia-Garcia, M.D., Ph.D., John J. Lopez, M.D.
Date: Tuesday, October 29, 2024
Time: 2:00-3:00 PM EDT
Session: Anatomy-derived Coronary Physiology – 2
Location: Moderated Abstracts Station 2, Innovation & Exhibit Hall (Halls A-C)

Title: TCT 96: Coronary Computed Tomography Angiography for Percutaneous Coronary Intervention: Initial US Experience With FFR_{CT}-Based Virtual PCI for Pre-Procedural Planning
Presenters: Pedro Carvalho, M.D.
Moderators: Louis A. Cannon, M.D., Christopher Irobunda. M.D.
Date: Wednesday, October 30, 2024
Time: 9:00-9:56 AM EDT
Session: Novel Percutaneous Techniques
Location: Moderated Abstracts Station 6, Innovation & Exhibit Hall (Halls A-C)

Heartflow invites attendees to a lunch symposium, “Utilizing Coronary CTA & Heartflow AI to Non-Invasively Assess Anatomy, Physiology and Plaque,” led by a panel of well-respected physicians including Ziad A. Ali, M.D., Suzanne J. Baron, M.D., Nick Curzen, M.D., Jimmy Lee Kerrigan, M.D. and Akiko Maehara, M.D. The symposium will take place on Tuesday, October 29, 2024, from 12:30-1:30 PM EDT in the FDA Theater, Innovation & Exhibit Hall (Halls A-C).

About Heartflow, Inc.

Heartflow is transforming precision coronary care with the only AI-powered, non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFR_{CT}, which is now supported by the ACC/AHA Chest Pain Guideline, Heartflow continues to advance the diagnosis and management of CAD. Heartflow’s suite of non-invasive technologies includes its FFR_{CT} Analysis, Roadmap™ Analysis and Plaque Analysis. More than 500 peer-reviewed publications have validated our approach and more importantly, our technologies have helped clinicians diagnose and manage over 250,000 patients. For more information, visit www.Heartflow.com.

Media Contact

Elliot Levy
media@Heartflow.com

Investor Contact

Nick Laudico
VP of Business Development and Investor Relations
nlaudico@Heartflow.com